ABT.SW

Abbott Laboratories [ABT.SW] Stock Forecast

Q: What is Abbott Laboratories stock symbol ?

Abbott Laboratories is a US stock, located in North chicago of Il and trading under the symbol ABT.SW

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ABT.SW Stock Summary

Earnings are expected to rise 5.46% next year

ABT.SW's dividend payments are well covered by cash flows with cash payout ratio of 58.72%.

Profit margins (0.14%) are lower than the previous year (0.16%)

ABT.SW has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

In the News

ABT.SW Financial details

Company Rating

Strong Buy

Market Cap

175.63B

Income

5.8B

Revenue

41.51B

Book val./share

Cash/share

Dividend

1.96

Dividend %

1.76%

Employees

115K

Optionable

Shortable

Yes

Earnings

18 Jul 2023

P/E

33.44

Forward P/E

14.98

PEG

-37.25

P/S

4.68

P/B

5.29

P/C

P/FCF

24.88

Quick Ratio

1.23

Current Ratio

1.63

Debt / Equity

LT Debt / Equity

0.42

EPS (TTM)

3.65

EPS next Y

6.11

EPS next Q

EPS this Y

-0.75%

EPS next Y

67.36%

EPS next 5Y

67.36%

EPS last 5Y

24.16%

Revenue last 5Y

7.38%

Revenue Q/Q

-3.41%

EPS Q/Q

28.81%

SMA20

SMA50

-11.17%

SMA100

-9.41%

Inst Own

Inst Trans

ROA

ROE

16%

ROC

0.12%

Gross Margin

55%

Oper. Margin

17%

Profit Margin

14%

Payout

57%

Shs Outstand

1.74B

Shs Float

1.73B

Target Price

52W Range

98.0-121.0

52W High

-24.38%

52W Low

-6.63%

RSI

0.3

Rel Volume

Avg Volume

Volume

Perf Week

Perf Month

Perf Quarter

-9.41%

Perf Half Y

-9.41%

Beta

0.662913

Volatility

0%, 0%

Prev Close

Price

91.5

Change

ABT.SW Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	17.42	18.1	19.54	24.42	25.04
Net income per share	1.35	2.09	2.54	4.01	3.98
Operating cash flow per share	3.59	3.48	4.46	5.97	5.5
Free cash flow per share	2.79	2.55	3.23	4.9	4.48
Cash per share	2.33	2.35	4.04	5.81	5.83
Book value per share	17.39	17.64	18.51	20.29	21.04
Tangible book value per share	-6.54	-5.06	-3.12	0.03	2.09
Share holders equity per share	17.39	17.64	18.51	20.29	21.04
Interest debt per share	11.62	11.05	11.38	11.05	10.38
Market cap	121.36B	157.18B	205.33B	227.82B	190.49B
Enterprise value	137.08B	172.21B	218.14B	237.03B	198.32B
P/E ratio	51.25	42.63	45.68	32.22	27.48
Price to sales ratio	3.97	4.93	5.93	5.29	4.36
POCF ratio	19.26	25.62	25.99	21.63	19.88
PFCF ratio	24.74	34.94	35.87	26.34	24.41
P/B Ratio	3.98	5.06	6.26	6.36	5.19
PTB ratio	3.98	5.06	6.26	6.36	5.19
EV to sales	4.48	5.4	6.3	5.5	4.54
Enterprise value over EBITDA	19.55	25.86	28.73	22.05	18.54
EV to operating cash flow	21.76	28.07	27.61	22.5	20.7
EV to free cash flow	27.94	38.29	38.11	27.41	25.41
Earnings yield	0.02	0.02	0.02	0.03	0.04
Free cash flow yield	0.04	0.03	0.03	0.04	0.04
Debt to equity	1.19	1.18	1.21	1.09	1.02
Debt to assets	0.54	0.54	0.55	0.52	0.5
Net debt to EBITDA	2.24	2.26	1.69	0.86	0.73
Current ratio	1.62	1.44	1.72	1.85	1.63
Interest coverage	4.42	7.87	10.71	17.19	22.3
Income quality	2.66	1.66	1.76	1.49	1.38
Dividend Yield	0.02	0.01	0.01	0.01	0.02
Payout ratio	0.83	0.62	0.57	0.45	0.48
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.08	0.08	0.07	0.06	0.07
Intangibles to total assets	0.63	0.59	0.53	0.48	0.45
Capex to operating cash flow	-0.22	-0.27	-0.28	-0.18	-0.19
Capex to revenue	-0.05	-0.05	-0.06	-0.04	-0.04
Capex to depreciation	-0.43	-0.54	-0.65	-0.53	-0.54
Stock based compensation to revenue	0.02	0.02	0.02	0.01	0.02
Graham number	22.97	28.81	32.51	42.78	43.39
ROIC	0.05	0.07	0.09	0.14	0.14
Return on tangible assets	0.09	0.13	0.13	0.18	0.17
Graham Net	-15.14	-14.88	-14.16	-12.18	-10.1
Working capital	5.62B	4.8B	8.53B	11.13B	9.74B
Tangible asset value	-11.47B	-8.92B	-5.53B	54M	3.65B
Net current asset value	-21.82B	-20.92B	-19.1B	-14.93B	-12.31B
Invested capital	0.64	0.61	0.6	0.53	0.48
Average receivables	5.22B	5.3B	5.92B	6.45B	7.68B
Average payables	2.69B	3.11B	3.6B	4.18B	4.51B
Average inventory	3.7B	4.06B	4.66B	5.08B	5.67B
Days sales outstanding	61.86	62.07	67.65	54.97	74.26
Days payables outstanding	85.46	89.71	96	86.8	87.85
Days of inventory on hand	109.05	119.06	121.93	101.54	117.71
Receivables turnover	5.9	5.88	5.4	6.64	4.92
Payables turnover	4.27	4.07	3.8	4.21	4.15
Inventory turnover	3.35	3.07	2.99	3.59	3.1
ROE	0.08	0.12	0.14	0.2	0.19
Capex per share	-0.79	-0.93	-1.23	-1.07	-1.02

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	6.79	6.43	8.34	5.81	5.61
Net income per share	1.4	1.15	1.15	0.59	0.76
Operating cash flow per share	1.18	1.38	2.23	1.34	0
Free cash flow per share	1	1.16	1.85	0.99	0
Cash per share	4.66	5.3	7.94	5.85	0
Book value per share	20.22	20.84	28.59	21.11	0
Tangible book value per share	0.13	1.36	2.2	2.1	0
Share holders equity per share	20.22	20.84	28.59	21.11	0
Interest debt per share	9.83	9.63	13.22	10.23	0
Market cap	208.07B	191.59B	135.67B	189.86B	180.76B
Enterprise value	217.49B	199.42B	142.49B	197.69B	0
P/E ratio	21.26	23.74	23.64	45.95	34.29
Price to sales ratio	17.49	17.02	13.03	18.81	18.55
POCF ratio	100.76	79.5	48.8	81.62	0
PFCF ratio	119.31	94.33	58.66	110.64	0
P/B Ratio	5.88	5.25	3.8	5.18	0
PTB ratio	5.88	5.25	3.8	5.18	0
EV to sales	18.28	17.71	13.69	19.59	0
Enterprise value over EBITDA	62.1	67.26	60.35	105.83	0
EV to operating cash flow	105.32	82.75	51.26	84.99	0
EV to free cash flow	124.71	98.19	61.6	115.2	0
Earnings yield	0.01	0.01	0.01	0.01	0.01
Free cash flow yield	0.01	0.01	0.02	0.01	0
Debt to equity	1.08	1.03	1.03	1.02	0
Debt to assets	0.52	0.51	0.51	0.5	0
Net debt to EBITDA	2.69	2.64	2.89	4.19	0
Current ratio	1.85	2.01	1.86	1.63	0
Interest coverage	24.89	22.42	20.58	19.76	29.02
Income quality	0.84	1.19	1.94	2.25	0
Dividend Yield	0	0	0.01	0	0
Payout ratio	0.34	0.41	0.58	0.8	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.06	0.06	0.08	0.07	0.07
Intangibles to total assets	0.48	0.46	0.46	0.45	0
Capex to operating cash flow	-0.16	-0.16	-0.17	-0.26	0
Capex to revenue	-0.03	-0.03	-0.04	-0.06	0
Capex to depreciation	-0.39	-0.46	-0.57	-0.76	0
Stock based compensation to revenue	0.03	0.01	0.01	0.01	0
Graham number	25.21	23.24	27.2	16.8	0
ROIC	0.05	0.04	0.03	0.02	0
Return on tangible assets	0.06	0.05	0.04	0.03	0
Graham Net	-12.56	-11.33	-15.5	-10.14	0
Working capital	10.78B	12.56B	11.48B	9.74B	0
Tangible asset value	225M	2.38B	2.75B	3.65B	0
Net current asset value	-14.95B	-12.53B	-12.07B	-12.31B	0
Invested capital	0.48	0.46	0.46	0.48	0
Average receivables	6.83B	7.19B	6.8B	7.64B	0
Average payables	4.58B	4.63B	4.31B	4.37B	0
Average inventory	5.42B	5.8B	5.82B	5.95B	0
Days sales outstanding	54.32	57.56	55.4	79.21	0
Days payables outstanding	85.85	81.97	80.36	90.27	0
Days of inventory on hand	102.71	107.62	111.48	120.96	0
Receivables turnover	1.66	1.56	1.62	1.14	0
Payables turnover	1.05	1.1	1.12	1	0
Inventory turnover	0.88	0.84	0.81	0.74	0
ROE	0.07	0.06	0.04	0.03	0
Capex per share	-0.18	-0.22	-0.37	-0.35	0

ABT.SW Dividend History

ABT.SW Frequently Asked Questions

What is Abbott Laboratories stock symbol ?

Abbott Laboratories is a US stock , located in North chicago of Il and trading under the symbol ABT.SW

What is Abbott Laboratories stock quote today ?

Abbott Laboratories stock price is $91.5 today.

Is Abbott Laboratories stock public?

Yes, Abbott Laboratories is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Market Capitalization 175.63B
Employee 115K
CEO Mr. Robert B. Ford
Headquarters North Chicago,IL,US
IPO Date 1937-03-01
Website https://www.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.